Overview
Summit Therapeutics is a Miami-based biopharmaceutical oncology company developing ivonescimab, licensed from Akeso for the US, Canada, Europe, Japan, Latin America, the Middle East and Africa. Its BLA for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC after a 3rd-generation EGFR TKI was accepted by the FDA with a PDUFA goal date of November 14, 2026. Summit is hiring its US sales leadership and key-account team ahead of a potential launch.
Hiring snapshot
Hiring by specialty
Open roles
Newest first, from Summit Therapeutics’s careers page.
- Oncology Regional Business Director - WestCalifornia10d ago$259k–$291k
- Oncology Regional Business Director - NortheastNew Jersey10d ago$259k–$291k
- Oncology Regional Business Director - Mississippi ValleyArkansas10d ago$259k–$291k
- Oncology Regional Business Director - Mid-AtlanticNorth Carolina10d ago$259k–$291k
- Oncology Regional Business Director - Great LakesChicago, Illinois10d ago$259k–$291k
- Oncology Regional Business Director -CentralTexas10d ago$259k–$291k
Divisions
Division information is pending company verification.Once Summit Therapeutics claims its page, you will see each division, who it calls on and how it pays.
Claim your pageMore from Summit Therapeutics
These sections fill in when Summit Therapeutics claims and verifies its page.